EA199800702A1 - Хиноксалиндионы - Google Patents
ХиноксалиндионыInfo
- Publication number
- EA199800702A1 EA199800702A1 EA199800702A EA199800702A EA199800702A1 EA 199800702 A1 EA199800702 A1 EA 199800702A1 EA 199800702 A EA199800702 A EA 199800702A EA 199800702 A EA199800702 A EA 199800702A EA 199800702 A1 EA199800702 A1 EA 199800702A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aryl
- compounds
- alkoxy
- ring
- halogen
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- -1 C-Alkoxy Chemical class 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical group C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
В изобретении предложены соединения формулы (I):и их фармацевтически приемлемые соли, где R представляет собой гетероарильную группу с 5 членами в кольце, содержащую 3 или 4 гетероатома азота, которая связана с кольцом хиноксалиндиона через кольцевой атом углерода или азота, или представляет собой гетероарильную группу с 6 членами в кольце, содержащую от 1 до 3 гетероатомов азота, которая связана с кольцом хиноксалиндиона через кольцевой атом углерода, причем любая из указанных групп является возможно бензоконденсированной и возможно замещенной, в том числе в бензоконденсированной части, 1 или 2 заместителями, каждый из которых произвольно выбран из С-Салкила, С-Салкенила, С-Сциклоалкила, галогена, гидрокси, С-Салкокси, С-Сциклоалкилокси, -СООН, С-Салкоксикарбонила, -CONRR, -NRR, -S(O)р(С-Салкила), -SONRR, арила, арилокси, арил(С-С)алкокси и гет, причем указанный С-Салкил возможно замещен С-Сциклоалкилом, галогеном, гидрокси, С-Салкокси, галоген(С-С)алкокси, С-Сциклоалкилокси, С-Сциклоалкил(С-С)алкоксигруппой, -СООН, С-Салкоксикарбонилом, -CONRR, -NRR-S(O)р(С-Салкилом), -SO(арилом), -SONRR, морфолино, арилом, арилокси, арил(С-С)алкокси или гет, причем указанный C-Салкенил возможно замещен арилом; Rи Rкаждый независимо выбран из Н, фтор-, хлор-, бром-, С-Салкила и галоген(С-С)алкила; Rи Rкаждый независимо выбран из Н, С-Салкила или, взятые вместе, они представляют собой C-Салкилен; р равно 0, 1 или 2; вместе с получением таких соединений, композициями, содержащими такие соединения, применениями таких соединений и промежуточными соединениями, применяемыми в синтезе таких соединений. Соединения полезны в качестве антагонистов NMDA рецептора при лечении острых нейродегенеративных и хронических неврологических
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
PCT/EP1997/000995 WO1997032873A1 (en) | 1996-03-09 | 1997-02-27 | Quinoxalinediones |
Publications (2)
Publication Number | Publication Date |
---|---|
EA199800702A1 true EA199800702A1 (ru) | 1999-04-29 |
EA001730B1 EA001730B1 (ru) | 2001-08-27 |
Family
ID=10790134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199800702A EA001730B1 (ru) | 1996-03-09 | 1997-02-27 | Хиноксалиндионы |
Country Status (42)
Country | Link |
---|---|
US (1) | US6376490B1 (ru) |
EP (1) | EP0885212B1 (ru) |
JP (1) | JP3110467B2 (ru) |
KR (1) | KR100288099B1 (ru) |
CN (1) | CN1103770C (ru) |
AP (1) | AP767A (ru) |
AR (1) | AR006119A1 (ru) |
AT (1) | ATE208773T1 (ru) |
AU (1) | AU717972B2 (ru) |
BG (1) | BG63340B1 (ru) |
BR (1) | BR9707851A (ru) |
CA (1) | CA2248366C (ru) |
CO (1) | CO4770976A1 (ru) |
CZ (1) | CZ292792B6 (ru) |
DE (1) | DE69708269T2 (ru) |
DK (1) | DK0885212T3 (ru) |
DZ (1) | DZ2188A1 (ru) |
EA (1) | EA001730B1 (ru) |
ES (1) | ES2163742T3 (ru) |
GB (1) | GB9605027D0 (ru) |
HN (1) | HN1998000034A (ru) |
HR (1) | HRP970132A2 (ru) |
HU (1) | HUP9900975A3 (ru) |
ID (1) | ID18112A (ru) |
IL (1) | IL125491A (ru) |
IS (1) | IS4811A (ru) |
MA (1) | MA26422A1 (ru) |
NO (1) | NO984058L (ru) |
NZ (1) | NZ331060A (ru) |
OA (1) | OA10850A (ru) |
PE (2) | PE43398A1 (ru) |
PL (1) | PL329032A1 (ru) |
PT (1) | PT885212E (ru) |
SI (1) | SI0885212T1 (ru) |
SK (1) | SK283467B6 (ru) |
TN (1) | TNSN97044A1 (ru) |
TR (1) | TR199801782T2 (ru) |
TW (1) | TW454004B (ru) |
UY (1) | UY24482A1 (ru) |
WO (1) | WO1997032873A1 (ru) |
YU (2) | YU39698A (ru) |
ZA (1) | ZA971987B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0003612A3 (en) * | 1997-02-27 | 2003-04-28 | Pfizer | Quinoxalinediones and pharmaceutical compositions containing them |
AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
DE10005150A1 (de) | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
RU2002133666A (ru) * | 2000-05-19 | 2007-05-10 | Мерк Патент ГмбХ (DE) | Производные триазола |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
MY145368A (en) | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
KR101170995B1 (ko) | 2004-02-06 | 2012-08-08 | 닛산 가가쿠 고교 가부시키 가이샤 | 에너지 저장 디바이스용 전극 및 그 제조 방법 |
JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
DK2091948T3 (da) | 2006-11-30 | 2012-07-23 | Probiodrug Ag | Nye inhibitorer af glutaminylcyclase |
US8603980B2 (en) | 2007-01-16 | 2013-12-10 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
CN101679383B (zh) * | 2007-05-17 | 2014-10-29 | 株式会社半导体能源研究所 | 三唑衍生物,和使用三唑衍生物的发光元件、发光器件和电子器件 |
EA022007B1 (ru) | 2009-09-11 | 2015-10-30 | Пробиодруг Аг | Гетероциклические производные в качестве ингибиторов глутаминилциклазы |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
CN104955809B (zh) * | 2013-02-07 | 2018-12-11 | 普雷斯特威克化学公司 | 取代的乙炔衍生物及其作为mGluR4的正变构调节剂的用途 |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2150417T3 (es) * | 1990-11-06 | 2000-12-01 | Yamanouchi Pharma Co Ltd | Derivados de pirazina fusionados. |
DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
HUP0003612A3 (en) * | 1997-02-27 | 2003-04-28 | Pfizer | Quinoxalinediones and pharmaceutical compositions containing them |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199800702A1 (ru) | Хиноксалиндионы | |
WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
YU17591A (sh) | Triazolni fungicidni agensi | |
EA199901062A1 (ru) | Производные хинолин-4-карбоксамида как антагонисты рецепторов нк-2 и нк-3 | |
ATE296300T1 (de) | Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel | |
KR910007883A (ko) | 퀴놀린 유도체, 그의 제조방법 및 용도 | |
CA2264065A1 (en) | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists | |
ES550801A0 (es) | Procedimiento para la obtencion de nuevos derivados de la pristinamicina ii b | |
ES2084972T3 (es) | Compuestos de imidazol, su preparacion y su uso como bloqueadores de los canales de calcio. | |
ATE95816T1 (de) | 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung. | |
EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b | |
NO885224L (no) | Fremgangsmaate for fremstilling av 1,4-disubstituerte-piperidinylderivater. | |
BR9812939B1 (pt) | compostos derivados ciclo-hexánicos difuncionalizados, processo de preparação de compostos quìmicos, e, composição farmacêutica. | |
NO900646L (no) | Fremgangsmaate for fremstilling av calsiumantagonister. | |
PT1214312E (pt) | Indoles 5-aminoalquilo e 5-aminocarbonilo substituidos | |
CO4750832A1 (es) | Nuevos derivados de quinolina | |
ATE196633T1 (de) | 5h- thiazolo(3,2-a)pyrimidin-5-on-derivate | |
TW288015B (en) | New chromene derivatives | |
UA37177C2 (ru) | Гетероциклические соединения или их фармацевтически приемлемые аддитивные соли кислоты или n-оксид гетероциклического соединения или его аддитивная соль кислоты | |
YU110692A (sh) | Tetrahidroizohinolinska jedinjenja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |